{
  "id": "clinical#screening_cues_cb4cfcb0",
  "content": "6C42 Disorders due to use of synthetic cannabinoids 443\n6C43 Disorders due to use of opioids 444\n6C44 Disorders due to use of sedatives, hypnotics or anxiolytics 444\n6C45 Disorders due to use of cocaine 445\n6C46 Disorders due to use of stimulants, including amfetamines,\nmethamfetamine and methcathinone 445\n6C47 Disorders due to use of synthetic cathinones 445\n6C48 Disorders due to use of caffeine 446\n6C49 Disorders due to use of hallucinogens 446\n6C4A Disorders due to use of nicotine 446\n6C4B Disorders due to use of volatile inhalants 447\n6C4C Disorders due to use of mdma or related drugs, including mda 447\n6C4D Disorders due to use of dissociative drugs, including ketamine and\nphencyclidine (PCP) 447\n6C4E Disorders due to use of other specified psychoactive substances,\nincluding medications 448\n6C4F Disorders due to use of multiple specified psychoactive substances,\nincluding medications 448\n6C4G Disorders due to use of unknown or unspecified psychoactive\nsubstances 448\n6C4H Disorders due to use of non-psychoactive substances 448\n6C4Z Disorders due to substance use, unspecified 448\nDiagnostic requirements for disorders due to substance use 455\nEpisode of harmful psychoactive substance use 455\nHarmful pattern of psychoactive substance use 458\nSubstance dependence 463\nix",
  "metadata": {
    "source": "WHO ICD-11",
    "url": "https://icd.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "screening_cues",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General â€” Screening Cues 6C42 Disorders due to use of synthetic cannabinoids 443\n6C43 Disorders due to use of opioids 444\n6C44 Disorders due to use of sedatives, hypnotics or anxiolytics 444\n6C45 Disorders due to use of cocaine 445\n6C46 Disorders due to use of stimulants, including amfetamines,\nmethamfetamine and methcathinone 445\n6C47 Disorders due to use of synthetic cathinones 445\n6C48 Disorders due to use of caffeine 446\n6C49 Disorders due to use of hallucinogens 446\n6C4A Disorders due to use of nicotine 446\n6C4B Disorders due to use of volatile inhalants 447\n6C4C Disorders due to use of mdma or related drugs, including mda 447\n6C4D Disorders due to use of dissociative drugs, including ketamine and\nphencyclidine (PCP) 447\n6C4E Disorders due to use of other specified psychoactive substances,\nincluding medications 448\n6C4F Disorders due to use of multiple specified psychoactive substances,\nincluding medications 448\n6C4G Disorders due to use of unknown or unspecified psychoactive\nsubstances 448\n6C4H Disorders due to use of non-psychoactive substances 448\n6C4Z Disorders due to substance use, unspecified 448\nDiagnostic requirements for disorders due to substance use 455\nEpisode of harmful psychoactive substance use 455\nHarmful pattern of psychoactive substance use 458\nSubstance dependence 463\nix 6c42 disorders due to use of synthetic cannabinoids 443\n6c43 disorders due to use of opioids 444\n6c44 disorders due to use of sedatives, hypnotics or anxiolytics 444\n6c45 disorders due to use of cocaine 445\n6c46 disorder..."
}